Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 5, 2016, Pages 3187-3192

  Shields, Ryan K ^a,b   Clancy, Cornelius J ^a,b,c   Press, Ellen G ^a   Nguyen, M Hong ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM; CIPROFLOXACIN; COLISTIN; DORIPENEM; ERTAPENEM; GENTAMICIN; MEROPENEM; VABORBACTAM; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTEREMIA; BONE INFECTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PRIMARY INFECTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SECONDARY INFECTION; SOFT TISSUE INFECTION; URINARY TRACT INFECTION; VERY ELDERLY; WOUND INFECTION; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; PATHOGENICITY;

ADULT; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTEREMIA; CARBAPENEMS; FEMALE; HUMANS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED;

EID: 84964937558     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02638-15     Document Type: Article

References (34)

1. Almaghrabi R, Clancy CJ, Doi Y, Hao B, Chen L, Shields RK, Press EG, Iovine NM, Townsend BM, Wagener MM, Kreiswirth B, Nguyen MH. 2014. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside modifying enzymes, which exert varying effects on plazomicin and other agents. Antimicrob Agents Chemother 58:4443-4451. http://dx.doi.org/10.1128/AAC.00099-14.
2. Clancy CJ, Hao B, Shields RK, Chen L, Perlin DS, Kreiswirth BN, Nguyen MH. 2014. Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes. Antimicrob Agents Chemother 58:3521-3525. http://dx.doi.org/10.1128/AAC.01949-13.
3. Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, Woodford N. 2011. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 66:48-53. http://dx.doi.org/10.1093/jac/dkq408.
4. Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, Jenkins SG, Calfee DP. 2011. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 55: 5893-5899. http://dx.doi.org/10.1128/AAC.00387-11.
5. Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, Pontes- Moreno A, López-Cerero L, Pascual A, Natera C, Rodríguez M, Salcedo I, Rodríguez-López F, Rivero A, Rodríguez-Baño J. 2015. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother 70:905-913. http://dx.doi.org /10.1093/jac/dku432.
6. McHenry MC, Gavan TL, VanOmmen RA, Hawk WA. 1971. Therapy with gentamicin for bacteremic infections: results with 53 patients. J Infect Dis 124(Suppl):S164-S173.
7. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. 1995. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 39:650-655. http://dx.doi.org/10.1128/AAC.39.3.650.
8. Riff LJ, Jackson GG. 1971. Pharmacology of gentamicin in man. J Infect Dis 124(Suppl):S98-S105.
9. Panidis D, Markantonis SL, Boutzouka E, Karatzas S, Baltopoulos G. 2005. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 128:545-552. http://dx.doi.org/10.1378/chest.128.2.545.
10. Pitt HA, Roberts RB, Johnson WD, Jr. 1973. Gentamicin levels in the human biliary tract. J Infect Dis 127:299-302. http://dx.doi.org/10.1093 /infdis/127.3.299.
11. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI document M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Gilbert DN, Chambers HF, Eliopoulos GM, Saag MS. 2014. The Sanford guide to antimicrobial therapy, 44th ed. Antimicrobial Therapy, Inc. Sperryville, VA.
13. Horan TC, Andrus M, Dudeck MA. 2008. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36:309-332. http://dx.doi.org/10.1016/j.ajic.2008.03.002.
14. Lorentzen H, Kallehave F, Kolmos HJ, Knigge U, Bülow J, Gottrup F. 1996. Gentamicin concentrations in human subcutaneous tissue. Antimicrob Agents Chemother 40:1785-1789.
15. Labovitz E, Levison ME, Kaye D. 1974. Single-dose daily gentamicin therapy in urinary tract infection. Antimicrob Agents Chemother 6:465-470. http://dx.doi.org/10.1128/AAC.6.4.465.
16. McCabe WR, Jackson GG. 1962. Gram-negative bacteremia: I. Etiology and ecology. Arch Intern Med 110:847-855.
17. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Clancy CJ, Chen L, Shields RK, Zhao Y, Cheng S, Chavda KD, Hao B, Hong JH, Doi Y, Kwak EJ, Silveira FP, Abdel-Massih R, Bogdanovich T, Humar A, Perlin DS, Kreiswirth BN, Hong Nguyen M. 2013. Epidemiology and molecular characterization of bacteremia due to carbapenemresistant Klebsiella pneumoniae in transplant recipients. Am J Transplant 13:2619-2633. http://dx.doi.org/10.1111/ajt.12424.
19. Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV, Tolwani AJ, Waikar SS, Weisbord SD. 2013. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 61:649-672. http://dx.doi.org/10.1053/j.ajkd.2013.02.349.
20. Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. 2014. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 20:862-872. http://dx.doi.org/10.1111 /1469-0691.12697.
21. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, Maiuro G, Tedeschi S, Celani L, Cardellino CS, Spanu T, Marchese A, Ambretti S, Cauda R, Viscoli C, Viale P, ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). 2015. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 70:2133-2143.
22. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D, Skoutelis A. 2014. Carbapenemase- producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58:2322-2328. http://dx.doi.org/10.1128 /AAC.02166-13.
23. Shields RK, Nguyen MH, Potoski BA, Press EG, Chen L, Kreiswirth BN, Clarke LG, Eschenauer GA, Clancy CJ. 2015. Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia. Antimicrob Agents Chemother 59:1797-1801. http://dx.doi.org/10.1128/AAC.03894-14.
24. Clancy CJ, Chen L, Hong JH, Cheng S, Hao B, Shields RK, Farrell AN, Doi Y, Zhao Y, Perlin DS, Kreiswirth BN, Nguyen MH. 2013. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother 57:5258-5265. http://dx.doi.org/10.1128/AAC.01069-13.
25. de Oliveira MS, de Assis DB, Freire MP, Boas do Prado GV, Machado AS, Abdala E, Pierrotti LC, Mangini C, Campos L, Caiaffa Filho HH, Levin AS. 2015. Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins. Clin Microbiol Infect 21:179e1-179e7.
26. Shields RK, Clancy CJ, Gillis LM, Kwak EJ, Silveira FP, Massih RC, Eschenauer GA, Potoski BA, Nguyen MH. 2012. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One 7:e52349. http://dx.doi.org/10.1371/journal.pone.0052349.
27. Giacobbe DR, Del Bono V, Trecarichi EM, De Rosa FG, Giannella M, Bassetti M, Bartoloni A, Losito AR, Corcione S, Bartoletti M, Mantengoli E, Saffioti C, Pagani N, Tedeschi S, Spanu T, Rossolini GM, Marchese A, Ambretti S, Cauda R, Viale P, Viscoli C, Tumbarello M, ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). 2015. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect 21:1106.e1-1106.e8. http://dx.doi.org/10.1016/j.cmi.2015.08.001.
28. Morrill HJ, Pogue JM, Kaye KS, LaPlante KL. 2015. Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis 2:ofv050. http://dx.doi.org/10.1093/ofid/ofv050.
29. Moore RD, Lietman PS, Smith CR. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155:93-99. http://dx.doi.org/10 .1093/infdis/155.1.93.
30. Blaser J, Stone BB, Groner MC, Zinner SH. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 31:1054-1060. http://dx.doi.org/10.1128/AAC.31.7.1054.
31. Valcke Y, Pauwels R, Van der Straeten M. 1990. Pharmacokinetics of antibiotics in the lungs. Eur Respir J 3:715-722.
32. Bailey JA, Virgo KS, DiPiro JT, Nathens AB, Sawyer RG, Mazuski JE. 2002. Aminoglycosides for intra-abdominal infection: equal to the challenge? Surg Infect (Larchmt) 3:315-335. http://dx.doi.org/10.1089 /109629602762539544.
33. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. 2012. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55:943-950. http://dx.doi.org/10.1093/cid/cis588.
34. Nicolau DP. 2015. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. Expert Opin Invest Drugs 24:1261-1273. http://dx.doi.org/10.1517 /13543784.2015.1062873.